Clinical Trial

A Study to Evaluate the Efficacy and Safety of DA-302168S Tablets in Overweight/Obese Subjects

Study acronym: DA168
Completed Phase 2
View on ClinicalTrials.gov →
Summary
It is a multicenter, randomized, double-blind, placebo-controlled phase II clinical trial to evaluate the safety and efficacy of DA-302168S tablets in overweight and obese adults.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-04-23; most recent amendment 2026-05-26.
Status change: Active, Not Recruiting → Completed 2026-05-26
Status change: Not Yet Recruiting → Active, Not Recruiting 2025-06-23
Trial Details
NCT Number NCT06953063
Lead Sponsor Chendu DIAO Pharmaceutical Group CO., LTD.
Conditions Overweight and Obesity
Enrollment 250 participants
Start Date 2025-05-15
Primary Completion 2025-12-15 (estimated)
Study Completion 2025-12-15 (estimated)
Updated on ClinicalTrials.gov 2026-05-28